Cedric O’Gorman

Efficacy and Safety of Lumateperone for Treatment of Schizophrenia

Christoph U. Correll, Robert E. Davis, Michal Weingart et al. · JAMA Psychiatry · 2020 · 276 citations · Full text

Determinants of different aspects of everyday outcome in schizophrenia: The roles of negative symptoms, cognition, and functional capacity

Martin Strassnig, Tenko Raykov, Cedric O’Gorman et al. · Schizophrenia Research · 2015 · 171 citations · Full text

Psychiatry, Risk Prediction, Psychotic Disorder +11

Findings of a U.S. National Cardiometabolic Screening Program Among 10,084 Psychiatric Outpatients

Christoph U. Correll, Benjamin G. Druss, Ilise Lombardo et al. · Psychiatric Services · 2010 · 108 citations

Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: A randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder

Jeffrey Miceli, Thomas G. Tensfeldt, Thomas Shiovitz et al. · Clinical Therapeutics · 2010 · 44 citations

Psychiatry, Psychotic Disorder, Qtc Interval +10

Effects of Oral Ziprasidone and Oral Haloperidol on QTc Interval in Patients with Schizophrenia or Schizoaffective Disorder

Jeffrey Miceli, Thomas G. Tensfeldt, Thomas Shiovitz et al. · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · 2010 · 42 citations